Table 2. Erythropoiesis during blood... | American Society of Hematology

Table 2.

Erythropoiesis during blood loss and erythropoietin therapy

Patients (n/sex)	Total EPO dose (U/kg)	Blood removed		Baseline RBC (m)	Blood produced		Iron therapy	Reference
Patients (n/sex)	Total EPO dose (U/kg)	Units	RBC (mL)	Baseline RBC (m)	RBC (mL)	Expansion (%)	Iron therapy	Reference
10/F	900 SQ	3.4	435	1285	358	28	IV	22
24	900 IV	5.2	864	1949	621	32	PO	16
10/F	1800 SQ	4.3	526	1293	474	37	IV	22
26	1800 IV	5.5	917	2032	644	32	PO	16
11/F	3600 IV	4.9	809	1796	701	39	PO	14, 15
12/M	3600 IV	5.9	1097	2296	1102	48	PO	14, 15
23	3600 IV	5.4	970	2049	911	45	PO	14, 15
18	3600 IV	5.6	972	2019	856	42	PO	16
1/M	4200 SQ	8	1600	2241	1764	79	Hemochromatosis	23

Patients (n/sex)	Total EPO dose (U/kg)	Blood removed		Baseline RBC (m)	Blood produced		Iron therapy	Reference
Patients (n/sex)	Total EPO dose (U/kg)	Units	RBC (mL)	Baseline RBC (m)	RBC (mL)	Expansion (%)	Iron therapy	Reference
10/F	900 SQ	3.4	435	1285	358	28	IV	22
24	900 IV	5.2	864	1949	621	32	PO	16
10/F	1800 SQ	4.3	526	1293	474	37	IV	22
26	1800 IV	5.5	917	2032	644	32	PO	16
11/F	3600 IV	4.9	809	1796	701	39	PO	14, 15
12/M	3600 IV	5.9	1097	2296	1102	48	PO	14, 15
23	3600 IV	5.4	970	2049	911	45	PO	14, 15
18	3600 IV	5.6	972	2019	856	42	PO	16
1/M	4200 SQ	8	1600	2241	1764	79	Hemochromatosis	23

Data are expressed as means.